Cantex Pharmaceuticals Overview
- Year Founded
-
2002

- Status
-
Private
- Employees
-
2

- Latest Deal Type
-
2ndary - Private
- Investors
-
1
Cantex Pharmaceuticals General Information
Description
Developer of biopharmaceutical technologies designed to improve the treatment of cancers and other life-threatening disorders. The company's biopharmaceutical technologies modify and repurpose existing drugs and create novel, proprietary, safe and effective therapeutics, enabling physicians to enhance the safety and effectiveness of existing cancer treatments.
Contact Information
Website
www.cantex.comCorporate Office
- 1792 Bell Tower Lane
- Weston, FL 33326
- United States
Corporate Office
- 1792 Bell Tower Lane
- Weston, FL 33326
- United States
Cantex Pharmaceuticals Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
9. Secondary Transaction - Private | 01-Sep-2022 | Completed | Clinical Trials - Phase 2 | |||
8. Later Stage VC (Series D) | 24-Nov-2014 | Completed | Clinical Trials - Phase 2 | |||
7. Secondary Transaction - Private | Completed | Clinical Trials - Phase 2 | ||||
6. Later Stage VC (Series C) | 23-Apr-2014 | Completed | Clinical Trials - Phase 2 | |||
5. Later Stage VC (Series C) | 04-Aug-2010 | Completed | Clinical Trials - Phase 2 | |||
4. Grant | 31-Dec-2009 | Completed | Clinical Trials - Phase 2 | |||
3. Later Stage VC | 13-Aug-2007 | Completed | Clinical Trials - Phase 2 | |||
2. Early Stage VC (Series B) | 25-Aug-2006 | $5.92M | $9.5M | Completed | Clinical Trials - Phase 2 | |
1. Early Stage VC (Series A) | 12-Aug-2002 | $3.62M | $3.62M | Completed | Startup |
Cantex Pharmaceuticals Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series D | ||||||||
Series C | ||||||||
Series B | ||||||||
Series A2 | 1,359,060 | $0.001000 | 8% | $1.49 | $1.49 | 1x | $1.49 | 0.48% |
Series A1 | 1,600,000 | $0.001000 | 8% | $1 | $1 | 1x | $1 | 0.56% |
Cantex Pharmaceuticals Comparisons
Industry
Financing
Details
Cantex Pharmaceuticals Competitors (93)
One of Cantex Pharmaceuticals’s 93 competitors is Byondis, a Corporation company based in Nijmegen, Netherlands.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Byondis | Corporation | Nijmegen, Netherlands | ||||
Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
Agios Pharmaceuticals | Formerly VC-backed | Cambridge, MA | ||||
ArriVent Biopharma | Formerly VC-backed | Newtown Square, PA | ||||
Nektar Therapeutics | Formerly VC-backed | San Francisco, CA |
Cantex Pharmaceuticals Patents
Cantex Pharmaceuticals Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-11648235-B1 | Treatment of glioblastoma | Active | 30-Dec-2022 | ||
US-20240216333-A1 | Treatment of glioblastoma | Inactive | 30-Dec-2022 | ||
US-10322096-B2 | Disulfiram and metal salt staggered oral dosing regimen and staggered-release oral unit dosage forms | Active | 26-Oct-2016 | ||
US-20200038345-A1 | Disulfiram and metal salt staggered oral dosing regimen and staggered-release oral unit dosage forms | Active | 26-Oct-2016 | ||
CA-3041857-A1 | Disulfiram and metal salt staggered oral dosing regimen and staggered-release oral unit dosage forms | Pending | 26-Oct-2016 | A61K31/145 |
Cantex Pharmaceuticals Signals
Cantex Pharmaceuticals Investors (1)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
Qualifying Therapeutic Discovery Project | Not-For-Profit Venture Capital |
Cantex Pharmaceuticals FAQs
-
When was Cantex Pharmaceuticals founded?
Cantex Pharmaceuticals was founded in 2002.
-
Where is Cantex Pharmaceuticals headquartered?
Cantex Pharmaceuticals is headquartered in Weston, FL.
-
What is the size of Cantex Pharmaceuticals?
Cantex Pharmaceuticals has 2 total employees.
-
What industry is Cantex Pharmaceuticals in?
Cantex Pharmaceuticals’s primary industry is Pharmaceuticals.
-
Is Cantex Pharmaceuticals a private or public company?
Cantex Pharmaceuticals is a Private company.
-
What is Cantex Pharmaceuticals’s current revenue?
The current revenue for Cantex Pharmaceuticals is
. -
How much funding has Cantex Pharmaceuticals raised over time?
Cantex Pharmaceuticals has raised $51.3M.
-
Who are Cantex Pharmaceuticals’s investors?
Qualifying Therapeutic Discovery Project has invested in Cantex Pharmaceuticals.
-
Who are Cantex Pharmaceuticals’s competitors?
Byondis, Adaptimmune Therapeutics, Agios Pharmaceuticals, ArriVent Biopharma, and Nektar Therapeutics are some of the 93 competitors of Cantex Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »